Precision BioSciences, Inc., a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, announced
Welcome to your Weekly Dose of Health Tech Innovation!Stay ahead with the latest breakthroughs revolutionizing healthcare—from AI diagnostics to remote care solutions.We bring you expert-curated insights,
Precision BioSciences, Inc., a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases,
Welcome to your Daily Dose of Health Tech Innovation!Stay ahead with the latest breakthroughs revolutionizing healthcare—from AI diagnostics to remote care solutions.We bring you expert-curated insights,
Precision BioSciences has been given Orphan Drug Designation by the U.S. Food and Drug Administration for its new treatment, PBGENE DMD, which is being developed
Precision BioSciences, a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for diseases with high unmet need,
